CCTG

LY.16

NCT01650701

LY.16

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Any Stage

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Lenalidomide (CC-5013)

Immunomodulatory drug (IMiD) (p.o.)

Treatment Arms

o Experimental: Lenalidomide + Rituximab

o Active Comparator: Control